Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994828 | 0.80 | ACP3 (0.61) | TSHRFFAR1ALDH1A1CYP1A2 | |
| SCHEMBL4344854 | 0.79 | KEAP1 (0.50) | TSHRNPSR1FFAR1CYP2C19 | |
| SCHEMBL4347612 | 0.76 | GRM8 (0.41) | TSHRGRM8GRM6GRM4 | |
| SCHEMBL340008 | 0.74 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL11499183 | 0.74 | ACP3 (0.57) | TSHR | |
| Phosphoric Acid SCHEMBL28176644 | 0.73 | GABRA1 (0.52) | TSHRALDH1A1 | |
| SCHEMBL878984 | 0.72 | KEAP1 (0.56) | NPSR1FFAR1 | |
| Bicarbonate SCHEMBL14635340 | 0.71 | GABRA1 (0.55) | TSHRALDH1A1 | |
| Bicarbonate SCHEMBL29051241 | 0.71 | GABRA1 (0.55) | TSHRALDH1A1 | |
| Hydrogen Peroxide SCHEMBL10890655 | 0.71 | GABRA1 (0.60) | TSHRNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| EP-1832594-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT FINANCE BVI LTD (VG) | 2011-05-18 | — | — | EP | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832594-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | TSHR 142/4885NPSR1 740/4885FFAR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.